Equities

Stella Pharma Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4888:TYO

Stella Pharma Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)438.00
  • Today's Change57.00 / 14.96%
  • Shares traded2.70m
  • 1 Year change-14.95%
  • Beta2.1074
Data delayed at least 15 minutes, as of Feb 18 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2025202520242023
OPERATIONS
Net income(138)(761)(776)
Depreciation/depletion353535
Non-Cash items616.58(1.29)
Cash taxes paid, supplemental2.862.853.63
Cash interest paid, supplemental4.082.082.58
Changes in working capital182(157)(85)
Total cash from operations140(877)(828)
INVESTING
Capital expenditures(12)(11)(29)
Other investing and cash flow items, total3001.97(0.6)
Total cash from investing288(9.01)(30)
FINANCING
Financing cash flow items(4.53)0.1014
Total cash dividends paid------
Issuance (retirement) of stock, net942388438
Issuance (retirement) of debt, net(216)(160)(160)
Total cash from financing721228292
NET CHANGE IN CASH
Foreign exchange effects------
Net change in cash1,149(657)(566)
Net cash-begin balance/reserved for future use2,0122,6703,236
Net cash-end balance/reserved for future use3,1612,0122,670
SUPPLEMENTAL INCOME
Depreciation, supplemental353535
Cash interest paid, supplemental4.082.082.58
Cash taxes paid, supplemental2.862.853.63
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.